|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Association of plasminogen activator inhibitor-1 and low-density lipoprotein heterogeneity as a risk factor of atherosclerotic cardiovascular disease with triglyceride metabolic disorder: a pilot cross-sectional study.
|
28692480 |
2017 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In this patient, without traditional risk factors for atherosclerosis, eight mutations and polymorphisms in six different genes were identified: polymorphism of factor V Leiden (1691 GA), factor II prothrombin (20210 GA), methylenetetrahydrofolate reductase (MTHFR, 677 CT and 1298 AC), plasminogen activator inhibitor 1 (PAI-1) polymorphism 4G/5G and glycoprotein VI (GP6, 13254 TC, Ser219Pro).
|
28382527 |
2017 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Common variation of the DNA sequence in the promoter region, such as that occurring in the human apolipoprotein A-I and plasminogen activator inhibitor(-1) genes, may account for subtle differences in serum lipid levels and risk of atherosclerotic vascular disease in the general population.
|
8743897 |
1996 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Fibrinogen, factor VII and PAI-1 genotypes and the risk of coronary and peripheral atherosclerosis: Edinburgh Artery Study.
|
10235438 |
1999 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In this study, we aimed to investigate the effect of tPA (tissue plasminogen activator) and PAI-1 (plasminogen activator inhibitor) antigen concentrations and 4G/5G polymorphism of the PAI-1 gene on the development of atherosclerosis in SLE patients.
|
21719525 |
2011 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Therefore, we performed this study to better assess the relationship between PAI-1 genetic variations and atherosclerosis.
|
29908999 |
2018 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
We and others have hypothesized that the increased PAI-1 may contribute to acceleration of atherosclerosis in this condition and in other states characterized by insulin resistance as well.
|
8281664 |
1994 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The results indicate that ghrelin inhibits both basal and TNF-alpha-induced PAI-1 production via NF-kappaB pathway in HepG2 cells, and suggest that the peptide plays a therapeutic role in atherosclerosis, especially in obese patients with insulin resistance, in whom ghrelin levels were reduced.
|
18700166 |
2008 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Plasminogen activator inhibitor ( PAI -1) is associated with excessive fibrin accumulation, thrombus formation, and atherosclerosis.
|
30371230 |
2018 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Insulin-resistant states are characterized by accelerated atherosclerosis and are associated with increased plasma concentrations of insulin and plasminogen activator inhibitor type 1 (PAI-1).
|
9386151 |
1997 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, PCB126 exposure in MCD-fed mice led to increased plasma inflammatory markers such as Icam-1, plasminogen activator inhibitor-1 and proatherogenic trimethylamine-N-oxide, suggesting inflammation of the peripheral vasculature that is characteristic of atherosclerosis.
|
28973532 |
2017 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Plasminogen activator inhibitor type-1 (PAI-1) has already been associated with atherosclerosis; myocardial infarction; and cardiovascular disease risk factors such as obesity, insulin resistance, and dyslipidemia.
|
20127289 |
2010 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Plasminogen activator inhibitor type 1 (PAI-1) is a major physiologic regulator of the fibrinolytic system and has recently gained recognition as a modulator of inflammation and atherosclerosis.
|
16968709 |
2006 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, in addition to the markers of insulin resistance and smoking habit, gene variants of PAI-1 and ACE account for a significant portion of the between-individual variability of circulating PAI-1 antigen concentrations in a general population without clinical evidence of atherosclerosis.
|
9555861 |
1998 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this paper, we have studied the contribution of the plasminogen activation system in the development of atherosclerosis by cross-breeding apoE3-Leiden mice, which have a human-like lipid profile, with mice deficient in PAI-1 (plasminogen-activator inhibitor-1), u-PA (urokinase plasminogen activator), and t-PA (tissue plasminogen activator).
|
14515193 |
2003 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Expression of a paternal history of premature myocardial infarction on fibrinogen, factor VIIC and PAI-1 in European offspring--the EARS study. European Atherosclerosis Research Study Group.
|
8052959 |
1994 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Negative correlations between antioxidative defense parameters and BMI, abdominal obesity, insulin secretion, systolic blood pressure and atherogenic lipid factors, as well as correlations between PAI-1 and insulin resistance and basal glycemia in the metabolic syndrome group contribute to accelerated atherosclerosis.
|
17848118 |
2007 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interleukin-6 and plasminogen activator inhibitor-1 did not provide incremental value to fibrinogen when examining the associations with degree of atherosclerosis.
|
27755007 |
2017 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Compared with normal pairs, the tissue content of PAI-1 (ng) was increased in fatty streak lesions (n = 3, normal 35 +/- 12, fatty streak 50 +/- 8, P < or = .05); stable to decreased in moderate atherosclerosis (n = 3, normal 34 +/- 3, moderate 22 +/- 7, P = .16); and increased in severe atherosclerosis (n = 6, normal 48 +/- 9, severe 85 +/- 19, P < or = .05).
|
9409325 |
1997 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
This overview summarizes the current knowledge on plasminogen activator inhibitor-1 (PAI-1) in the progression of atherosclerosis and the influence of MMPs in aneurysm formation.
|
11795260 |
2001 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
CTD_human |
Atheroprotective Mechanisms Activated by Fluid Shear Stress in Endothelial Cells.
|
12677255 |
2002 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Finally, we explored the causal effect of PAI-1 on cardiovascular risk factors including metabolic and subclinical atherosclerosis measures.
|
28550093 |
2017 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Plasminogen activator inhibitor-1 (PAI-1) has been regarded as a risk factor for thrombosis and atherosclerosis.
|
29253845 |
2017 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
PAI-1 is paracrine secretion of pro- and antiinflammatory cytokines, thereby playing a possible role in the adiposity-related inflammation and atherosclerosis.
|
19033264 |
2009 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Increased production of plasminogen activator inhibitor-1 (PAI-1) in plaques plays a role in the pathogenesis of atherosclerosis.
|
12063175 |
2002 |